Shopping Cart
Remove All
Your shopping cart is currently empty
ATF3-IN-1 is an inhibitor of both ferroptosis and ATF3. It mitigates oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, offering protection against ischemic stroke. ATF3-IN-1 can reduce ischemia/reperfusion (I/R) injury and enhance neuron survival, demonstrating neuroprotective effects, making it valuable for ischemic stroke research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | ATF3-IN-1 is an inhibitor of both ferroptosis and ATF3. It mitigates oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, offering protection against ischemic stroke. ATF3-IN-1 can reduce ischemia/reperfusion (I/R) injury and enhance neuron survival, demonstrating neuroprotective effects, making it valuable for ischemic stroke research. |
| In vitro | ATF3-IN-1 (Compound 1c) at concentrations of 0.1-2 μM alleviates ischemia/reperfusion (I/R) injury in primary cortical neuron models of oxygen-glucose deprivation (OGD) by inhibiting oxidative stress and ferroptosis. It exhibits no cytotoxicity in rat cortical neurons not subjected to OGD. ATF3-IN-1 mitigates ferroptosis and reduces I/R injury in the primary cortical neuron OGD model through the ATF3/SLC7A11/GPX4 axis. |
| In vivo | ATF3-IN-1 (Compound 1c) (2 mg/kg, ICV, single administration) reduces infarct volume and promotes neurological recovery after brain ischemia/reperfusion (I/R) injury in a rat model of middle cerebral artery occlusion (MCAO) by modulating the ATF3/SLC7A11/GPX4 axis, oxidative stress, and ferroptosis. |
| Molecular Weight | 451.55 |
| Formula | C24H37NO7 |
| Cas No. | 2952703-90-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.